Jason Hale
Interventional Pain Medicine · Houston, TXNPI 1073045720
Payments from drug & device makers
Across 27 payments — averaging $652.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Relievant Medsystems, Inc.$1K
- Medtronic$181
- Nevro Corp.$149
- MML US, Inc.$147
- Nalu Medical, Inc.$147
- plus $511 from 4 others
What the payments were for
- Grants$15,00085%
- Travel & lodging$7374%
- Food & beverage$1,88211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 4 | $15,309 |
| Relievant Medsystems, Inc. | 8 | $1,177 |
| Medtronic | 4 | $181 |
| Nevro Corp. | 3 | $149 |
| MML US, Inc. | 1 | $147 |
| Nalu Medical, Inc. | 1 | $147 |
| Saluda Medical Americas, Inc. | 3 | $144 |
| Vertos Medical, Inc. | 1 | $125 |
| Globus Medical | 1 | $121 |
| GRT US Holding, Inc. | 1 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WAVEWRITER ALPHA$15,000
- Intracept$2,123
- ReActiv8$147
- Nalu Neurostimulation System$147
- Superion Indirect Decompression System$128
- INTELLIS$128
- mild Device Kit$125
- ELSA ATP$121
- Qutenza$120
- Omnia$110
- Evoke SCS$106
How this compares
$17,619 in reported general payments places this provider in the 70th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 350 | $4,035 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 155 | $1,589 |
| Celecoxib | 84 | $1,303 |
| Pregabalin | 42 | $1,200 |
| Tizanidine Hcl | 140 | $794 |
| Cyclobenzaprine Hcl | 50 | $736 |
| Meloxicam | 191 | $724 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 68 | $639 |
| Duloxetine Hcl | 29 | $431 |
| Methylprednisolone | 65 | $372 |
| Tramadol Hcl | 109 | $370 |
| Diclofenac Sodium | 11 | $114 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Houston
- Ioannis SkaribasHouston$979K
- Brian BruelHouston$219K
- George AtallahHouston$48K
- Shervin HarandiHouston$39K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Genaro GutierrezAustin$1.3M
- Chad StephensSouthlake$1.1M
- Duane GriffithTyler$730K
- Brannon FrankAustin$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.